Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Depreciation & Amortization (CF) (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Depreciation & Amortization (CF) data on record, last reported at $923000.0 in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 11.34% year-over-year to $923000.0; the TTM value through Dec 2025 reached $4.2 million, up 8.45%, while the annual FY2025 figure was $4.2 million, 8.45% up from the prior year.
  • Depreciation & Amortization (CF) reached $923000.0 in Q4 2025 per COLL's latest filing, down from $1.0 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $1.1 million in Q2 2025 and bottomed at $424000.0 in Q4 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $797700.0, with a median of $865000.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): surged 129.74% in 2021, then decreased 11.34% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $424000.0 in 2021, then skyrocketed by 94.58% to $825000.0 in 2022, then rose by 15.03% to $949000.0 in 2023, then rose by 9.69% to $1.0 million in 2024, then fell by 11.34% to $923000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $923000.0 in Q4 2025, $1.0 million in Q3 2025, and $1.1 million in Q2 2025.